Heteroresistance (HR) to colistin is especially concerning in settings where multi-drug-resistant (MDR)
No takes yet. Share an insight, caveat, or question.
Braspenning et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: